| ID | 10321 |
| Vaccine Name | WIBP-CorV |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Inactivated |
| Vaccine Status | Phase 3 |
| Manufacturer | Sinopharm, Wuhan Institute of Biological Products |
| Year of Manufacturing | 2021 |
| Manufacturing Country | China |
| Age | 18 years and above |
| Dosage | 2 doses 21 days apart |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | SARS-CoV-2 whole virus |
| Description | NA |
| Approving Organisation | NA |
| Collaborating Organisation | G42 Healthcare company, Abu Dhabi Health Services Company, Wuhan Institute of Biological Products Co. Ltd, Beijing Institute of Biological Products Co Ltd. |
| Other Countries | China, UAE |
| Trade Name | Zhongkangkewei |
| PMID | 33816047 |
| Clinical Trial ID | NCT04510207 |
| Reference Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ |
| Additional Links | https://clinicaltrials.gov/ct2/show/NCT04510207
|